top of page
Browse by category
Search
Weekly dose of semaglutide 7.2 mg can significantly improve weight loss and related health outcomes in adults living with obesity
A higher weekly dose of semaglutide (7.2 mg) can significantly improve weight loss and related health outcomes in adults living with...
Half of people stop taking semaglutide within a year
A population-wide study presented at the Annual Meeting of the European Association for the Study of Diabetes, Vienna, reports that half...
Overweight and obesity do not always increase the risk of an early mortality
The study of tens of thousands of people in Denmark found that those with a BMI in the overweight category, and even some of those living...
Adipokine Hypothesis theorises changes in biology of internal fat may be the leading cause of heart failure
Heart failure with preserved ejection fraction (HFpEF) appears to develop as a result of changes in the biology of a person’s internal...
Significant disparities in the availability of MBS services and the level of resident training and exposure
A global survey on general surgery resident involvement in metabolic and bariatric surgery (MBS) has reported that significant...
Semaglutide cuts risk of heart attack, stroke or death by 57% vs tirzepatide
Outcomes form the STEER real-world study have revealed that semaglutide 2.4 mg had 57% greater risk reduction for heart attack, stroke...
Browse by tag
bottom of page